Determining Severity Strata for Three Atopic Dermatitis Patient-Reported Outcome Questionnaires: Defining Severity Score Ranges for the Worst Pruritus Numerical Rating Scale and the Atopic Dermatitis Symptom and Impact Scales (ADerm-SS and ADerm-IS)

Jonathan I. Silverberg · Eric L. Simpson · Brian M. Calimlim · Leighann Litcher-Kelly · Xiaoran Li · Xiaowu Sun · Yael A. Leshem

Received: July 26, 2022 / Accepted: October 15, 2022 / Published online: November 4, 2022 © The Author(s) 2022

ABSTRACT

Introduction: Three patient-reported outcome (PRO) questionnaires—Worst Pruritus Numerical Rating Scale (WP-NRS), Atopic Dermatitis Symptom Scale (ADerm-SS), and Atopic Dermatitis Impact Scale (ADerm-IS)—were developed to assess the symptoms and impacts of atopic dermatitis (AD). Severity strata for these PROs are needed to aid in their interpretation.

Methods: Using data from a global, randomized, double-blind, placebo-controlled, phase 3 clinical trial (NCT03568318) of patients with moderate–severe AD (age ≥ 12 years), equipercentile linking analyses were conducted to define severity strata applying the Patient Global Impression of Severity as an anchor. Analyses were conducted separately for adults and adolescents, and then harmonized between the two age groups.

Results: The sample included 769 adults and 113 adolescents. For the WP-NRS, 0 was associated with absent, 1–2 with minimal, 3 with mild, 4–7 with moderate, and 8–10 with severe. For the ADerm-SS Skin Pain, 0 was associated with absent, 1 with minimal, 2 with mild, 3–6 with moderate, and 7–10 with severe. For ADerm-SS 7-Item Total Symptom Score (TSS-7), 0–1 was associated with absent, 2–11 with minimal, 12–22 with mild, 23–47 with moderate, and 48–70 with severe. For ADerm-IS Sleep, 0 was associated with absent, 1–3 with minimal, 4–6 with mild, 7–20 with moderate, and 21–30 severe.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s13555-022-00836-5.
with severe. For ADerm-IS Daily Activities, 0 was associated with absent, 1–2 with minimal, 3–7 with mild, 8–25 with moderate, and 26–40 with severe. For ADerm-IS Emotional State, 0 was associated with absent, 1–2 with minimal, 3–8 with mild, 9–22 with moderate, and 23–30 with severe.

**Conclusions:** These severity strata provide score interpretations of the WP-NRS, ADerm-SS, and ADerm-IS, translating these scores to simple and intuitive outcomes, which can inform clinical studies and clinical practice.

**Trial Registration Number:** NCT03568318.

**Keywords:** ADerm-SS; ADerm-IS; Atopic dermatitis; Patient-reported outcomes; Pruritus; Severity strata; Skin pain; Sleep

### INTRODUCTION

Atopic dermatitis (AD) is a chronic inflammatory skin disease affecting up to 30% of children and 10% of adults across different countries worldwide [1]. In addition to skin manifestations, AD is characterized by pruritus, skin pain, and sleep impacts [2]. There are currently no widely accepted biomarkers or objective measures of these symptoms, thus, they are best measured by patients themselves using patient-reported outcomes (PRO). In addition, prior research reported only modest correlations between clinician-evaluated AD lesions and patient-reported symptoms such as itch and pain [3, 4]. Therefore, it is important to assess these aspects using PRO questionnaires.

Prior to questionnaire development, a review of existing AD-specific instruments was conducted to determine whether there were any existing tools that could be implemented in a clinical trial for the assessment of symptoms and impacts of moderate to severe AD in adolescents and adults [5]. While AD-specific PRO questionnaires were developed and evaluated by other groups [6–10] [including the consensus group to harmonize core outcome measures for atopic eczema/dermatitis (HOME) [11, 12]], none of the reviewed questionnaires met the criteria of the research team for the evaluation of daily and weekly symptoms and impacts in a clinical trial setting for the target patient population. Thus, three novel PRO questionnaires for adolescents and adults with moderate to severe AD were developed on the basis of best measurement practices summarized in the US Food and Drug Administration’s 2009 PRO guidance [13–15]: Worst Pruritus Numerical Rating Scale (WP-NRS), Atopic Dermatitis Symptom Scale (ADerm-SS), and Atopic Dermatitis Impact Scale (ADerm-IS). Evidence of content validity [5, 16], psychometric performance, and score interpretation guidance (e.g., meaningful within person change) [17] has been demonstrated in adolescents and adults with moderate to severe AD.

It is important to translate PRO questionnaire scores into easily understandable reference points for clinicians and patients (i.e.,
interpretability), as performed for other patient- and clinician-reported assessments for AD [18–20]. This research sought to define severity strata not previously reported for the three PRO questionnaires described above that assess the daily/weekly signs, symptoms, and impacts of moderate to severe AD [5, 16, 17].

METHODS

Data

Data from a global, randomized, double-blind, placebo-controlled, multi-center phase 3 clinical trial (NCT03568318) involving 901 adolescents and adults with moderate to severe AD were used for this analysis. Ethical review at each clinical site was completed for the clinical trial study protocol, informed consent forms, and recruitment materials before enrollment (See Supplementary Material, Table 1 for details); the study design and patient population were described previously [21]. Participants with scores from the target PROs (WP-NRS, ADerm-SS, ADerm-IS) at baseline and one follow-up timepoint (week 2, 4, or 16) were included in the analyses.

Measures

Figure 1 summarized the content and the scoring generated by the three target PRO assessments. Details for each questionnaire are also provided below.

The WP-NRS is a single-item PRO questionnaire designed to assess the severity of worst/maximal itch over the past 24 h on an 11-point numerical rating scale (NRS), with scores ranging from 0 (No itch) to 10 (Worst imaginable itch). Higher scores indicate more severe itch.

The ADerm-SS is an 11-item PRO questionnaire designed to assess 11 signs and symptoms of AD at their worst over a 24-h recall period. All items are scored on an 11-point NRS from 0 [no (sign/symptom concept)] to 10 [worst possible (sign/symptom concept)]. This analysis focused on two scores calculated for the ADerm-SS: a single-item score for skin pain (ADerm-SS Skin Pain) and a seven-item Total Symptom Score (ADerm-SS TSS-7). The ADerm-SS Skin Pain score is the score of Item 3 and ranges from 0 to 10, with higher scores indicating worse skin pain. The ADerm-SS TSS-7 is calculated as the sum of Items 1–7. The ADerm-SS TSS-7 score ranges from 0 to 70, with higher scores indicating worse AD symptoms.

The ADerm-IS is a 10-item PRO questionnaire designed to assess a variety of impacts that patients experience from their AD across both a 24-h recall period (daily Items 1–3) and 7-day recall period (weekly Items 4–10). Three domain scores were calculated for the ADerm-IS: Sleep, Daily Activities, and Emotional State. The ADerm-IS Sleep, Daily Activities, and Emotional State scores were calculated as the sum of Items 1–3, Items 4–7, and Items 8–10, respectively. The ADerm-IS Sleep score ranges from 0 to 30, with higher scores indicating greater impacts on sleep. The ADerm-IS Daily Activities score ranges from 0 to 40, with higher scores indicating greater impacts on daily activities. The ADerm-IS Emotional State score ranges from 0 to 30, with higher scores indicating greater emotional impacts.

The Patient Global Impression of Severity (PGIS) was used as an anchor variable in the analyses and is a single-item PRO questionnaire assessing overall current disease severity on a 7-point verbal response scale where 0 indicates “absent: no symptoms” and 6 indicates “very severe: cannot be ignored and markedly limits my daily activities.” In these analyses, the PGIS was collapsed into five categories to simplify interpretation (Fig. 2). This assessment was developed to align with regulatory expectations and guidance [22] on what constitutes a good anchor measure; specifically, it is an assessment of the patient’s current state to minimize influences of recall, it is easy to interpret and correlated with the target assessments, and was completed at comparable timepoints during the trial.
Statistical Methods

Linking is a statistical method that maps values from an anchor instrument to the equivalent values on the target measure (or vice versa) \[23\]. Equipercentile linking, the method most commonly used in studies of linking \[24, 25\], was used to map WP-NRS, ADerm-SS, and ADerm-IS scores to collapsed PGIS severity categories. Analyses were conducted using pooled data from several timepoints (baseline, weeks 2, 4, and 16) to ensure scores represented the full range of response options on the target assessments and the PGIS. For target assessments completed daily, scores from the earliest day of each corresponding weekly visit window were used. Pearson correlations and 95% confidence intervals (CI) were calculated between PGIS and the scores from the target PRO questionnaires for both age groups to confirm the suitability of the PGIS as an anchor for the linking analyses. To evaluate whether a pooled severity strata set could be created, adult and adolescent correlation coefficients and their 95% CIs were assessed for similarity. No imputation of missing data was conducted for any of the questionnaires.

Score intervals were estimated separately for adolescents and adults, and then qualitatively evaluated to identify the severity strata that were applicable to both adults and adolescents. Specifically, a score of 0 was utilized to indicate “absent” unless results suggested otherwise. Additionally, upper severity thresholds were averaged between adults and adolescents, then rounded down to the nearest integer. If rounding down caused overlap with adjacent severity strata, the averaged value was rounded up.

Finally, the agreement of severity strata with the PGIS for adolescents and adults was assessed by the weighted kappa statistic (\(\kappa\)). All analyses were conducted in SAS, version 9.4 (SAS Institute, Cary, NC, USA).

RESULTS

Participant Demographics and Baseline Health Characteristics

The total sample analyzed \((N = 882)\) included adults \((n = 769)\) and adolescents \((n = 113)\) with moderate to severe AD. The mean age of
participants at baseline was $34.1 \pm 15.0$ years (range 12–75 years), and over half the sample was male (60.8%) and white (71.4%) (Table 1). On the basis of the clinician-assessed validated Investigator Global Assessment of AD (vIGA-AD), 46.8% and 53.2% of the sample were rated as moderate and severe at baseline, respectively (similar percentages were observed for both the adult and adolescent subgroups). Baseline scores on the PGIS and target PRO questionnaires were also similar for adults and adolescents (Table 2).

**Correlation of PGIS Anchor to the Target Assessments**

The WP-NRS, ADerm-SS Skin Pain and TSS-7, and ADerm-IS domain scores were moderately to strongly correlated ($r \geq 0.49$) with the PGIS for both adolescents and adults (See Supplementary Material, Table 2). While correlations were lower for the adolescent sample [range 0.49 (week 2 ADerm-SS Skin Pain and week 4 ADerm-IS Emotional State) to 0.70 (week 16 WP-NRS and ADerm-SS Skin Pain)], compared with adults [range 0.61 (week 2 ADerm-IS Sleep) to 0.79 (week 16 ADerm-SS TSS-7)], all correlations were at least moderate. Furthermore, the 95% CIs for adults and adolescents overlapped for all scores for at least one timepoint, supporting the consistency in the correlations. Therefore, the PGIS was determined to be an acceptable anchor for equipercentile linking.

**Identification of PRO Severity Strata by Age Group Separately and Combined**

Identified severity strata anchored to the PGIS are presented in Fig. 3 for adults and adolescents separately. In general, the severity strata are consistent across both adults and adolescents, and therefore Fig. 3 also presents the pooled severity strata applicable to both adults and adolescents after qualitative evaluation. Agreement of the combined adult and adolescent severity strata with the PGIS severity categories indicated that the agreement was acceptable ($\kappa > 0.4$) [26] when applying them to either age group (Table 3).

**DISCUSSION**

The results presented can be used to interpret scores generated by the WP-NRS, ADerm-SS, and ADerm-IS, which were developed to be completed by adolescents and adults with moderate to severe AD [5, 16, 17] in a clinical trial setting. Results were largely consistent between the adult and adolescent samples, though correlations between scales were lower for adolescents, and threshold scores for adolescents tended to be less severe than adults. There may be subtle differences in symptom experience and burden between adults and adolescents with AD [27, 28], which may affect how they score their condition. Another explanation for difference between age groups is that the ADerm-SS and

| Table 1 Demographic characteristics of the sample |
|-----------------------------------------------|
| **Demographic characteristic** | **Statistic** |
| Age (in years) | $n = 882$ |
| Mean (SD) | 34.1 (15.0) |
| Range | 12–75 |
| Sex | |
| Female | 346 (39.2%) |
| Male | 536 (60.8%) |
| Race | |
| American Indian or Alaskan Native | 6 (0.7%) |
| Asian | 184 (20.9%) |
| Black or African American | 49 (5.6%) |
| Native Hawaiian or Other Pacific Islander | 4 (0.5%) |
| White | 630 (71.4%) |
| Multiple | 9 (1.0%) |
| Ethnicity | |
| Hispanic or Latino | 76 (8.6%) |
| Not Hispanic or Latino | 806 (91.4%) |
| $SD$ standard deviation |
### Table 2
Score distribution of assessments at baseline ($N = 882$) for M16-047

| Score                        | Adults ($n = 769$) | Adolescents ($n = 113$) |
|------------------------------|--------------------|-------------------------|
| **Baseline vIGA-AD score**   |                    |                         |
| Moderate                     | 361 (46.9%)        | 52 (46.0%)              |
| Severe                       | 408 (53.1%)        | 61 (54.0%)              |
| **Baseline PGIS score**      |                    |                         |
| Absent                       | 2 (0.3%)           | 1 (0.9%)                |
| Minimal                      | 4 (0.5%)           | 7 (6.2%)                |
| Mild                         | 18 (2.3%)          | 5 (4.4%)                |
| Moderate                     | 117 (15.2%)        | 23 (20.4%)              |
| Moderately severe            | 205 (26.7%)        | 38 (33.6%)              |
| Severe                       | 269 (35.0%)        | 24 (21.2%)              |
| Very severe                  | 149 (19.4%)        | 13 (11.5%)              |
| Missing                      | 5 (0.7%)           | 2 (1.8%)                |
| **WP-NRS score**             |                    |                         |
| $N$                          | 769                | 113                     |
| Mean (SD)                    | 7.5 (1.8)          | 6.9 (2.3)               |
| Median                       | 8.0                | 7.0                     |
| Min–Max                      | 0.0–10.0           | 0.0–10.0                |
| Missing                      | 0 (0.0%)           | 0 (0.0%)                |
| **ADerm-SS Skin Pain score** |                    |                         |
| $N$                          | 769                | 113                     |
| Mean (SD)                    | 6.4 (2.3)          | 6.3 (2.4)               |
| Median                       | 6.7                | 6.7                     |
| Min–Max                      | 0.0–10.0           | 0.0–10.0                |
| Missing/no response          | 0 (0.0%)           | 0 (0.0%)                |
| **ADerm-SS TSS-7 score**     |                    |                         |
| $N$                          | 738                | 111                     |
| Mean (SD)                    | 46.8 (14.0)        | 44.6 (14.5)             |
| Median                       | 48.0               | 47.0                    |
| Min–Max                      | 0.0–70.0           | 1.0–70.0                |

*AD* atopic dermatitis, *ADerm IS* Atopic Dermatitis Impact Scale, *ADerm-SS* Atopic Dermatitis Symptom Scale, *PGIS* Patient Global Impression of Severity, *SD* standard deviation, *TSS-7* 7-Item Total Symptom Score, *vIGA-AD* validated Investigator Global Assessment of Atopic Dermatitis, *WP-NRS* Worst Pruritus Numerical Rating Scale

$vIGA-AD$ was completed by clinicians; an inclusion criteria of the clinical trial was that participants had moderate or severe AD based on vIGA-AD
ADerm-IS scales were originally developed on the basis of an adult content validation study, and were geared toward the experience of this age group [5]. Follow-up qualitative research was conducted with adolescents with moderate to severe AD to confirm that the questionnaires capture the patient experience for this younger group [16]; however, differences in disease perception between age groups require further research.

The verbal response scale utilized by the PGIS provides a framework for interpreting the scores of the target assessments, which is useful in understanding the clinical meaning of the scores in relation to patients’ overall AD severity. Defining severity strata was used for other clinical outcome assessments including PRO questionnaires in AD [18–20, 29–31], and this information can be used as a benchmark for comparison of scores between PRO questionnaires and also interpretation of scores in future clinical research for similar patients. The current strata for the WP-NRS and ADerm-SS Skin Pain scores are similar to results presented for other similar PRO questionnaires [30, 31] that use a 0–10 NRS; specifically, scores of less than 4 and 3 are associated with milder itch and skin pain, respectively. For the ADerm-SS TSS-7 and

**Fig. 3** Severity strata anchored to collapsed Patient Global Impression of Severity categories (adults and adolescents and pooled). Severity strata are based on the collapsed PGIS. Absent, light peach with grey text; Minimal, peach with grey text; Mild, orange with white text; Moderate, light red with white text; Severe, dark red with white text. The Moderate stratum corresponds to PGIS of Moderate and Moderately severe; the Severe stratum corresponds to PGIS of Severe and Very severe. ADerm IS Atopic Dermatitis Impact Scale, ADerm-SS Atopic Dermatitis Symptom Scale, PGIS Patient Global Impression of Severity, TSS-7 7-Item Total Symptom Score, WP-NRS Worst Pruritus Numerical Rating Scale

| Weighted kappa statistic | WP-NRS | ADerm-SS Skin Pain | ADerm-SS TSS-7 | ADerm-IS Sleep | ADerm-IS Daily Activities | ADerm-IS Emotional State |
|--------------------------|--------|------------------|----------------|----------------|--------------------------|-------------------------|
| Adolescents              | 0.574  | 0.535            | 0.604          | 0.551          | 0.551                    | 0.558                   |
| Adults                   | 0.757  | 0.684            | 0.786          | 0.681          | 0.687                    | 0.708                   |

ADerm IS Atopic Dermatitis Impact Scale, ADerm-SS Atopic Dermatitis Symptom Scale, TSS-7 7-Item Total Symptom Score, WP-NRS Worst Pruritus Numerical Rating Scale
ADerm-IS domain scores, the severity strata presented here may help researchers determine screening criteria and endpoints for future clinical research on moderate to severe AD.

While there are other analytic methods for linking [32, 33], the equipercentile linking method provides an automated, non-parametric, data-driven approach to identify severity strata that requires fewer restrictions and distributional assumptions [32–34] compared with anchor-based methods [18, 20, 29]. One strength of the current analyses was the ability to pool data from several timepoints during the clinical trial to ensure scores captured the full range of response options on both the PGIS and the target assessments. Another strength of the current analyses is the large sample and the inclusion of both adolescents and adults, which allowed separate investigation of adolescents and adults and maintained adequate data volume across each PGIS severity level for the analyses. One limitation of these analyses is the use of clinical trial data collected among individuals with moderate to severe AD at baseline, and thus it is unknown whether these results are generalizable to other contexts of use or broader patient populations. Another limitation is using the PGIS anchor (collapsing a 7-point response scale into five categories), which differs from other anchors used in prior AD research categorizing patients as clear, mild, moderate, or severe. Therefore, these analyses should be replicated using additional anchors and real-world data to confirm whether the severity bands are the same for a broader sample of individuals (i.e., based on gender, race, region, etc.) with AD in other settings. While using one cohesive set of interpretability bands for all age groups is practical, investigators may consider applying separate bands for different age groups as provided. In addition, further evaluation is needed if applying these severity strata to a target patient population that differs from those with moderate to severe AD, such as patients with mild AD or general pruritus.

While there are other disease-specific assessments for AD, most are intended to be completed during clinic visits and have longer recall periods to accommodate a less frequent administration schedule. If the research goal is to evaluate the signs, symptoms, and impacts of moderate to severe AD on a more granular level, then the current daily/weekly diary assessments could be useful in understanding how the severity of these concepts is experienced by patients in their daily lives.

CONCLUSIONS

The current analyses provide severity strata to interpret scores generated by the WP-NRS, ADerm-SS, and ADerm-IS completed by adolescents and adults with moderate to severe AD. These strata may help inform future research, including clinical trial endpoints and clinical practice treatment targets, and help patients and clinicians understand research findings to participate in shared decision making.

ACKNOWLEDGEMENTS

Funding. AbbVie Inc. funded this study, including the journal Rapid Service fee, and participated in the study design; study research; collection, analysis, and interpretation of data; and writing, reviewing, and approving of this publication.

Medical Writing, Editorial, and Other Assistance. The authors wish to acknowledge Catherine Foley, Masami Kelly, Sylvia Su, Paolo Medrano, Roger E Lamoureux, Jeffrey McDonald, and Christine Yip of Adelphi Values for their work in the development and evaluation of the ADerm-SS, ADerm-IS, and WP-NRS. This work was funded by AbbVie Inc.

Authorship. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Author Contributions. All authors had access to the data, and participated in the development, review, and approval, and in the
decision to submit this publication. All authors contributed to the study conception and design. Analyses were performed by Xiaowu Sun and Xiaoran Li. The first draft of the manuscript was written by Brian Calimlim and Leighann Litcher-Kelly and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript. No honoraria or payments were made for authorship.

Prior Presentation. This manuscript is based on work that was previously presented at the 11th Georg Rajka International Symposium on Atopic Dermatitis (ISAD 2021, Hybrid Meeting), April 19–20, 2021 (Silverberg JI, Simpson EL, Calimlim BM, Li X, Sun X, Leshem YA. Severity strata for Atopic Dermatitis Symptom Scale (ADerm-SS), Atopic Dermatitis Impact Scale (ADerm-IS), and Worst Pruritus Numerical Rating Scale (NRS)).

Disclosures. Jonathan I. Silverberg is an advisor, speaker, or consultant for AbbVie Inc., AFYX, Arena, Asana, BiomX, Bluefin, Bodewell, Boehringer Ingelheim, Celgene Corporation, Dermavant, Dermira, Eli Lilly, Galderma, GlaxoSmithKline, Hoth, Incyte, Kiniksa, Leo Pharma, Luna, Menlo Therapeutics, Novartis, Pfizer, RAPT, Regeneron Pharmaceuticals, and Sanofi. He is also a researcher for Galderma. Eric L. Simpson reports grants, personal fees, and non-financial support from Eli Lilly; grants and personal fees from Anacor Pharma, GlaxoSmithKline, Regeneron Pharmaceuticals, Sanofi Genzyme, Pfizer, Leo Pharma, Eli Lilly, and Valeant Pharmaceuticals; personal fees from AbbVie Inc., Celgene Corporation, Dermira, Galderma, Genentech, Leo Pharma, and Menlo Therapeutics; and grants from MedImmune, Novartis, Roivant Sciences, Tioga Pharmaceuticals, and Vanda Pharmaceuticals. Brian M. Calimlim is a full-time, salaried employee of AbbVie Inc. and owns AbbVie Inc. stock or stock options. Leighann Litcher-Kelly is employed by Adelphi Values LLC, which received payment from AbbVie Inc. to support the research activities presented in this publication. Yael A. Leshem has received honoraria or fees as a consultant from AbbVie Inc., Sanofi, Janssen, Pfizer, and Genentech, and as an advisory board member from Sanofi, Regeneron Pharmaceuticals, Pfizer, AbbVie Inc., and Dexcel Pharma; has received an independent research grant from AbbVie Inc.; and has, without personal compensation, provided investigator services for Eli Lilly, Pfizer, and AbbVie Inc.

Compliance with Ethics Guidelines. This secondary analysis uses de-identified data from a clinical trial, which was conducted in accordance with the principles of the Helsinki Declaration of 1964 and later amendments. Ethical review at each clinical site (see Supplemental Table 1) was completed for the clinical trial study protocol, informed consent forms, and recruitment materials, before enrollment [21].

Data Availability. The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Open Access. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
REFERENCES

1. Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab. 2015;66(Suppl 1): 8–16.

2. National Eczema Association. Atopic dermatitis 2016 [7 Sep 2021]. https://nationaleczema.org/eczema/types-of-eczema/atopic-dermatitis/. Accessed 27 Oct 2022.

3. Chopra R, Vakharia PP, Sacotte R, Patel N, Imamneni S, White T, et al. Relationship between EASI and SCORAD severity assessments for atopic dermatitis. J Allergy Clin Immunol. 2017;140(6):1708–10.e1.

4. Vakharia PP, Chopra R, Sacotte R, Patel KR, Singam V, Patel N, et al. Burden of skin pain in atopic dermatitis. Ann Allergy Asthma Immunol. 2017;119(6):548–52.e3.

5. Foley C, Tundia N, Simpson E, Teixeira HD, Litcher-Kelly L, Bodhani A. Development and content validity of new patient-reported outcome questionnaires to assess the signs and symptoms and impact of atopic dermatitis: the Atopic Dermatitis Symptom Scale (ADerm-SS) and the Atopic Dermatitis Impact Scale (ADerm-IS). Curr Med Res Opin. 2019;35(7):1139–48.

6. Gerbens LA, Prinsen CA, Chalmers JR, Drucker AM, von Kobyletzki LB, Limpens J, et al. Evaluation of the measurement properties of symptom measurement instruments for atopic eczema: a systematic review. Allergy. 2017;72(1):146–63.

7. Heinl D, Prinsen CA, Deckert S, Chalmers JR, Drucker AM, Ofenloch R, et al. Measurement properties of adult quality-of-life measurement instruments for eczema: a systematic review. Allergy. 2016;71(3):358–70.

8. Silverberg JI, DeLozier A, Sun L, Thysjen JP, Kim B, Yosipovitch G, et al. Psychometric properties of the itch numeric rating scale, skin pain numeric rating scale, and atopic dermatitis sleep scale in adult patients with moderate-to-severe atopic dermatitis. Health Qual Life Outcomes. 2021;19(1):247.

9. Taieb A, Boralevi F, Seneschal J, Merhand S, Georgescu V, Taieb C, et al. Atopic dermatitis burden scale for adults: development and validation of a new assessment tool. Acta Derm Venereol. 2015;95(6):700–5.

10. Yosipovitch G, Reaney M, Mastey V, Eckert L, Abbe A, Nelson L, et al. Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis. Br J Dermatol. 2019;181(4):761–9.

11. Chalmers JR, Simpson E, Apfelbacher CJ, Thomas KS, von Kobyletzki L, Schmitt J, et al. Report from the fourth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative). Br J Dermatol. 2016;175(1):69–79.

12. Spuls PI, Gerbens LAA, Simpson E, Apfelbacher CJ, Chalmers JR, Thomas KS, et al. Patient-Oriented Eczema Measure (POEM), a core instrument to measure symptoms in clinical trials: a Harmonising Outcome Measures for Eczema (HOME) statement. Br J Dermatol. 2017;176(4):979–84.

13. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, Center for Devices and Radiological Health. Guidance for industry patient-reported outcome measures: use in medical product development to support labeling claims. Silver Spring: Office of Communications, Division of Drug Information; 2009.

14. Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, Martin ML, Molsen E, et al. Content validity-establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: Part 1-Eliciting concepts for a new PRO instrument. Value Health. 2011;14(8):967–77.

15. Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, Martin ML, Molsen E, et al. Content validity-establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force Report: Part 2-Assessing respondent understanding. Value Health. 2011;14(8):978–88.

16. Silverberg JI, Simpson EL, McLaugherty M, Medrano P, Su S, Calimlim BM, et al. Content validity of the Atopic Dermatitis Symptom Scale (ADerm-SS) and Atopic Dermatitis Impact Scale (ADerm-IS) in adolescents to assess the symptoms and impacts of atopic dermatitis. In: Revolutionizing Atopic Dermatitis (RAD) Congress; 13–14 Dec 2020; Virtual.

17. Silverberg JI, Simpson EL, Litcher-Kelly L, McDonald J, Calimlim BM, Leshem YA. Psychometric evaluation of three patient-reported outcome questionnaires assessing the symptoms and impacts of atopic dermatitis in adults and adolescents. In: Revolutionizing Atopic Dermatitis (RAD) Congress; 13–14 Dec 2020; Virtual.

18. Chopra R, Vakharia PP, Sacotte R, Patel N, Imamneni S, White T, et al. Severity strata for Eczema Area and Severity Index (EASI), modified EASI, Scoring Atopic Dermatitis (SCORAD), objective
SCORAD, Atopic Dermatitis Severity Index and body surface area in adolescents and adults with atopic dermatitis. Br J Dermatol. 2017;177(5):1316–21.

19. Leshem YA, Hajar T, Hanifin JM, Simpson EL. What the Eczema Area and Severity Index score tells us about the severity of atopic dermatitis: an interpretability study. Br J Dermatol. 2015;172(5):1353–7.

20. Silverberg JI, Gelfand JM, Margolis DJ, Fonacier L, Boguniewicz M, Schwartz LB, et al. Severity strata for POEM, PO-SCORAD, and DLQI in US adults with atopic dermatitis. Ann Allergy Asthma Immunol. 2018;121(4):464-8.e3.

21. Reich K, Teixeira HD, de Bruin-Weller M, Bieber T, Soong W, Kabashima K, et al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2021;397(10290):2169–81.

22. US Food & Drug Administration. Patient-Focused Drug Development Guidance Public Workshop: Incorporating Clinical Outcome Assessments into Endpoints for Regulatory Decision-Making 12/06/2019 [04/27/2022]. https://www.fda.gov/media/132505/download. Accessed 27 Oct 2022.

23. Kolen MJ, Brennan RL. Testing equating, scaling, and linking: methods and practices. New York: Springer-Verlag; 2014.

24. Linn RL. Linking results of distinct assessments. Appl Meas Educ. 1993;6(1):83–102.

25. Leucht S, Kane JM, Etschel E, Kissling W, Hamann J, Engel RR. Linking the PANSS, BPRS, and CGI: clinical implications. Neuropsychopharmacol. 2006;31(10):2318–25.

26. McGee S. Evidence-based physical diagnosis e-book. Elsevier Health Sciences; 2021.

27. Grant L, Seiding Larsen L, Trennery C, Silverberg JI, Abramovits W, Simpson EL, et al. Conceptual model to illustrate the symptom experience and humanistic burden associated with atopic dermatitis in adults and adolescents. Dermatitis. 2019;30(4):247–54.

28. McCleary K. Understanding the lived experience of eczema: the "Voice of the Patient" Report on the eczema patient-focused drug development meeting: More Than Skin Deep; 03/2020 [05/19/2022]. http://www.morethanskindeep-eczema.org/uploads/1/2/5/3/125377765/mtd_report_-_digital_file.pdf. Accessed 27 Oct 2022.

29. Charman CR, Venn AJ, Ravenscroft JC, Williams HC. Translating Patient-Oriented Eczema Measure (POEM) scores into clinical practice by suggesting severity strata derived using anchor-based methods. Br J Dermatol. 2013;169(6):1326–32.

30. Silverberg JI. Validity and reliability of a novel numeric rating scale to measure skin-pain in adults with atopic dermatitis. Arch Dermatol Res. 2021;313(10):855–61.

31. Vakharia PP, Chopra R, Sacotte R, Patel N, Immenni S, White T, et al. Severity strata for five patient-reported outcomes in adults with atopic dermatitis. Br J Dermatol. 2018;178(4):925–30.

32. Bjorner JB. Solving the Tower of Babel problem for patient-reported outcome measures: comments on: linking scores with patient-reported health outcome instruments: a validation study and comparison of three linking methods. Psychometrika. 2021;86(3):747–53.

33. Schalet BD, Lim S, Cell D, Choi SW. Linking scores with patient-reported health outcome instruments: a validation study and comparison of three linking methods. Psychometrika. 2021;86(3):717–46.

34. Price L, Lurie A, Wilkins C. EQUIPERCENT: a SAS program for calculating equivalent scores using the equipercentile method. Appl Psychol Meas. 2001;25:332.